Washington – A jury in Philadelphia on Tuesday ordered the multinational Johnson & Johnson (J&J) to pay compensation of 8,000 million dollars to a man for the effects of the neuroleptic Risperdal, as reported by The Wall Street Journal (WSJ).
This is the greatest compensation to date against J&J of the more than 13,000 lawsuits against people who point to Risperdal for causing them as gynecomastia children, a condition that causes the enlargement of the mammary glands in men.
Johnson & Johnson, according to the lawsuits, was aware of this side effect of Risperdal but did not warn its clients of the risk.RELATED
This neuroleptic treats bipolar disorder, schizophrenia and irritability associated with autism and was one of Johnson & Johnson's best-selling products in the United States while commercialized exclusively until 2008.
In a statement, the New Jersey-based multinational said it would resort to "this excessive and unfounded verdict," which it also described as "very disproportionate" and showed its confidence that it will be "reversed."
Judges normally reduce the compensation set by jurors when studying the resources of those affected.
This Tuesday is the last judicial and financial setback against Johnson & Johnson, after several fines and economic agreements in court for various reasons.
Last week, for example, the multinational agreed a fine of 20.4 million with two counties in the state of Ohio that allows it to avoid a federal process that aims to hold the pharmaceutical industry responsible for the opioid crisis.
Johnson & Johnson marketed the Duragesic and Nucynta painkillers and continues to accumulate hundreds of other claims for the opioid epidemic.
Last August, a judge in the state of Oklahoma ordered J&J to pay $ 572 million in what was considered the first judicial process of magnitude in the country for the opioid crisis.
Last year, a jury in Missouri ordered J&J to pay $ 4.690 million to 22 women and their families who blame the multinational's baby powder for causing ovarian cancer.
Johnson & Johnson has appealed these verdicts.